Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Standardized discharge orders after stroke: results of the quality improvement in stroke prevention (QUISP) cluster randomized trial.

  • Read more about Standardized discharge orders after stroke: results of the quality improvement in stroke prevention (QUISP) cluster randomized trial.

Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.

  • Read more about Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

  • Read more about Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

Status report: the Annals in 2010.

  • Read more about Status report: the Annals in 2010.

Interleukin-6 genotype and risk for cerebral palsy in term and near-term infants.

  • Read more about Interleukin-6 genotype and risk for cerebral palsy in term and near-term infants.

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

  • Read more about Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Glutathione peroxidase activity modulates recovery in the injured immature brain.

  • Read more about Glutathione peroxidase activity modulates recovery in the injured immature brain.

Treatment of childhood arterial ischemic stroke.

  • Read more about Treatment of childhood arterial ischemic stroke.

Activated Src kinases interact with the N-methyl-D-aspartate receptor after neonatal brain ischemia.

  • Read more about Activated Src kinases interact with the N-methyl-D-aspartate receptor after neonatal brain ischemia.

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

  • Read more about Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Pagination

  • Previous page ‹‹
  • Page 4
  • Next page ››
Subscribe to Annals of neurology

Pediatrics Home

MAKE A GIFT

© 2026 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                   Accessibility  Privacy Policy  Terms of Use  A-Z Website List